Amgen first-quarter profit, revenue rise
April 23 (Reuters) - Amgen Inc on Tuesday reported higher first-quarter profit on increased sales of its drug Enbrel for rheumatoid arthritis and newer medicines to help prevent bone fractures.
The world's largest biotechnology company posted a net profit of $1.43 billion, or $1.88 per share, compared with a profit of $1.18 billion, or $1.48 per share, a year ago.
Excluding one time items, Amgen had adjusted earnings of $1.96. Analysts on average expected $1.84 per share, according to Thomson Reuters I/B/E/S.
- Exclusive: Secret contract tied NSA and security industry pioneer |
- U.S. aircraft hit by gunfire in South Sudan as conflict worsens
- With Fed out of the way, what's next on Wall Street?
- Analysis: Lost Brazil order raises threat to Boeing fighter jets
- Four men arrested in deadly N.J. shopping mall carjacking